Data from the phase II NP30179 expansion study demonstrated that, after a median follow-up of more than 12 months, fixed-duration glofitamab—an investigational CD20xCD3 T cell-engaging bispecific antibody—induced durable complete responses in patients with relapsed or refractory diffuse large B-cell lymphoma who had received a median of three prior therapies.
The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Owen Witte with the twelfth annual Harrington Prize for Innovation in Medicine.
